ARVN

6.5303.12%
AR

Andrew R. Saik

CFO & Treasurer

Mr. Andrew R. Saik is an Independent Director of Milestone Pharmaceuticals Inc. since July 14, 2024. He serves as Chief Financial Officer & Treasurer at Arvinas, Inc. since June 24, 2024. He served as Chief Financial Officer at Intercept Pharmaceuticals, Inc. since June 2021. He served as Chief Financial Officer and Treasurer at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 23, 2020 until June 18, 2021. Mr. Saik served as Chief Financial Officer and Director of PDS Biotechnology Corporation from March 15, 2019 until March 23, 2020. He served as Chief Financial Officer of PDS Biotechnology, Inc. (Formerly Edge Therapeutics, Inc.) since November 2017 until March 15, 2019. He has extensive accounting, finance and general management experience at domestic and international companies. Mr. Saik served as Chief Financial Officer of Vertice Pharma, LLC since August 2015 until July 2017. Mr. Saik served as the Chief Financial Officer at Auxilium Pharmaceuticals Inc. from August 18, 2014 to January 29, 2015. Mr. Saik was responsible for all financial and information technology activities and relationships and play a critical leadership role in executing Auxilium's diversification and growth strategy. He served as Senior Vice President, Finance and Treasurer at Auxilium Pharmaceuticals Inc (formerly known as Endo Health Solutions Inc.) from February 2013 to August 2014, where he was responsible for internal and external reporting, global consolidations of M&A transactions, cash management, debt financing and risk management. He has hands-on experience, including shaping financial strategy, leading successful M&A transactions, integrating global company and product acquisitions and cash management. Prior to Auxilium Pharmaceuticals, Mr. Saik served in senior financial management roles with progressive responsibility at Valeant Pharmaceuticals International (formerly known as ICN Pharmaceuticals Inc.) from January 2001 to July 2002, where he served as its Senior Vice President of Finance and was the overall finance lead for the acquisition and integration of the Johnson & Johnson and Sanofi-Aventis dermatology business units in the U.S. and Canada, enabling Valeant to build the largest dermatology business in North America. Previously at Valeant, he served as Chief Financial Officer of Specialty Pharmaceuticals Division which included the U.S. Canada and Australia. Mr. Saik was a Finance Manager and analyst at Nexgenix, Inc. from October 1999 to 1999 and the Atlantic Richfield Corporation from June 1996 to October 1999. He holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.

Positions